三一生物技术公司收到关于纳斯达克全球精选市场对公众持股最低市值要求及纳斯达克最低出价要求的不合规通知-动脉网

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares and Nasdaq Minimum Bid Price Requirement

GlobeNewswire 等信源发布 2025-03-14 16:30



可切换为仅中文







DUBLIN, March 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice today from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), requiring that listed securities maintain a minimum bid price of US $1.00 per share, based on the closing bid price of the Company’s American depositary shares (“ADSs”) for the last 30 consecutive business days.

都柏林，2025年3月14日（环球新闻社）—— 商业阶段的生物技术公司Trinity Biotech plc（纳斯达克股票代码：TRIB），专注于人类诊断和糖尿病管理解决方案，包括可穿戴生物传感器，今日收到纳斯达克股票市场有限责任公司（“纳斯达克”）通知，称公司未遵守纳斯达克上市规则5450(a)(1)，该规则要求上市证券维持每股最低1.00美元的出价，这是基于公司美国存托股份（“ADSs”）过去连续30个交易日的收盘出价。

The Company also received notice today that the Company no longer meets the requirement in Nasdaq Listing Rule 5450(b) that listed securities maintain a minimum market value of publicly held shares (“MVPHS”) of US $15,000,000, based on Nasdaq’s review of the Company’s MVPHS for the last 30 consecutive business days..

公司今日还收到通知，基于纳斯达克对公司过去连续30个营业日的公众持股最低市值（“MVPHS”）的审查，公司已不再符合纳斯达克上市规则5450(b)中规定的上市公司证券需维持至少15,000,000美元公众持股市值的要求。

These notices have no immediate effect on the listing of the Company’s ADSs, which will continue to trade at this time on the Nasdaq Global Select Market under the symbol “TRIB.”

这些通知对公司的ADS上市没有直接影响，公司ADS将继续在纳斯达克全球精选市场以“TRIB”代码进行交易。

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), Trinity has a period of 180 calendar days, or until September 10, 2025 to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s ADSs must meet or exceed US $1.00 for at least ten consecutive business days during this 180-calendar day period.

根据纳斯达克上市规则5810(c)(3)(A)，Trinity有180个日历日的期限，或直到2025年9月10日，以重新符合最低出价要求。为了重新符合要求，在这180个日历日期间，公司的美国存托股份（ADS）的收盘出价必须至少连续十个营业日达到或超过1.00美元。

In the event Trinity does not regain compliance, the Company may be eligible for an additional 180 calendar day grace period if it meets the continued listing requirement for MVPHS (US $15,000,000) and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price and provides written notice to Nasdaq of its intention to cure the deficiency during the second compliance period..

如果Trinity未能恢复合规，只要公司满足纳斯达克资本市场除股价以外的所有其他持续上市要求（包括1500万美元的最低公众持股市值MVPHS）及初始上市标准，并向纳斯达克提交书面通知表明其在第二个合规期内弥补不足的意愿，则可能有资格获得额外180个日历日的宽限期。

In accordance with Nasdaq Listing Rule 5810(c)(3)(D), the Company has a period of 180 calendar days, or until September 10, 2025, to regain compliance with the MVPHS requirement. To regain compliance, the Company’s MVPHS must exceed US $15,000,000 for a minimum of 10 consecutive business days. In the event that the deficiency continues for 180 days, the Company may seek to apply for a transfer to The Nasdaq Capital Market exchange if it meets the requirements for continued listing thereon.

根据纳斯达克上市规则5810(c)(3)(D)，公司有180个日历日的期限，或直到2025年9月10日，以重新符合MVPHS要求。为重新符合要求，公司的MVPHS必须在至少连续10个交易日内超过1,500万美元。如果该不足状况持续180天，公司可以在满足相关继续上市要求的情况下，申请转至纳斯达克资本市场交易所。

If the Company does not regain compliance with the minimum MVPHS requirement by September 10, 2025 or transfer to The Nasdaq Capital Market, Nasdaq will provide written notification to the Company that its ADSs are subject to delisting. At that time, the Company may appeal the relevant delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules.

如果公司未能在2025年9月10日之前重新符合最低MVPHS要求或转至纳斯达克资本市场，纳斯达克将向公司发出书面通知，告知其ADS将面临退市。届时，公司可以根据适用的纳斯达克上市规则中规定的程序，向听证会小组上诉相关的退市决定。

However, there can be no assurance that if the Company does appeal the delisting determination by Nasdaq to the hearings panel, that such appeal would be successful..

然而，无法保证如果公司确实就纳斯达克的退市决定向听证小组提出上诉，这样的上诉是否会成功。

Trinity’s management intends to actively monitor the bid price and MVPHS for its ADSs and intends to cure the deficiency within the prescribed grace period. During this time, the Company expects that the ADSs of the Company will continue to be listed and trade on the Nasdaq Global Market. The Company’s management is evaluating various options available to regain compliance and maintain its continued listing..

Trinity的管理层打算积极监控其ADS的出价价格和MVPHS，并计划在规定的宽限期内纠正不足之处。在此期间，公司预计其ADS将继续在纳斯达克全球市场上市并交易。公司的管理层正在评估各种可选方案，以重新达到合规要求并保持其持续上市状态。

The Company’s business operations are not affected by these notices.

公司的业务运作不受这些通知的影响。

Forward-Looking Statements

前瞻性声明

This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations.

本发布包含构成1995年《私人证券诉讼改革法案》（“改革法案”）意义内的“前瞻性声明”的陈述，包括但不限于与Trinity Biotech的现金状况、财务资源及未来增长潜力、新或计划中产品在市场上的接受度和渗透率、以及未来经常性收入和运营结果相关的声明。

Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar import, and do not reflect historical facts.

Trinity Biotech声称其前瞻性声明受到《改革法案》中安全港条款的保护。这些前瞻性声明通常以“可能”、“相信”、“预计”、“预期”或类似含义的词语为特征，并不反映历史事实。

Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and of our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, the impact of the spread of COVID-19 and its variants, the possible impact of changes in U.S.

本发布文件中包含的特定前瞻性陈述可能会受到风险和不确定性的影响，包括但不限于我们利用Waveform交易及近期收购的能力、我们继续在纳斯达克股票市场上市的能力、我们未来实现盈利运营的能力、新冠疫情及其变异毒株传播的影响、美国政策变化可能带来的影响。

Government funding for HIV tests produced by Trinity Biotech, potential excess inventory levels and inventory imbalances at the Company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free.

政府对Trinity Biotech生产的HIV测试的资金支持、潜在的过多库存水平及公司分销商的库存失衡、Trinity Biotech设施或制造业务相关的损失或系统故障、汇率波动对国际运营的影响、季度经营业绩的波动、对供应商的依赖、市场对其产品和服务的接受度、其产品的持续开发、所需的政府批准、与大规模商业生产和分销相关的产品风险。

About Trinity Biotech

关于Trinity Biotech

Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc.

Trinity Biotech是一家处于商业化阶段的生物技术公司，专注于糖尿病管理解决方案和人类诊断，包括可穿戴生物传感器。该公司开发、收购、制造和销售诊断系统，包括试剂和仪器，服务于诊断市场的床旁护理和临床实验室领域，并且最近通过收购Waveform Technologies Inc.的生物传感器资产进入了可穿戴生物传感器行业。

and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide.

并打算开发一系列生物传感器设备和相关服务，首先是一款连续血糖监测产品。我们的产品用于检测传染病，并量化血清、血浆和全血中的糖化血红蛋白 A1c 和其他化学参数的水平。Trinity Biotech 在美国直接销售，并通过覆盖全球 75 个国家的国际分销商和战略合作伙伴网络进行销售。

For further information, please see the Company’s website: .

如需更多信息，请参阅公司网站：。

www.trinitybiotech.com

。

Contact:

联系人：

Trinity Biotech plc

三一生物技术公司

LifeSci Partners, LLC

生命科学合伙人有限公司

Louise Tallon